3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Warts
5
Condylomata Acuminata
2
Virus Diseases
1
Skin Diseases, Viral
1
Skin Diseases, Infectious
1
Skin Diseases
1
Sexually Transmitted Diseases, Viral
1
Sexually Transmitted Diseases
1
Papillomavirus Infections
1
Interventions
human papillomavirus vaccine, L1 type 16, 18
36
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
29
Papillomavirus Vaccines
22
Vaccines
11
Human Papillomavirus Recombinant Vaccine nonavalent
11
Radiotherapy, Intensity-Modulated
7
Human Papillomavirus DNA Tests
7
Colposcopy
7
Cisplatin
7
Educational Status
6
Carboplatin
6
Blood Specimen Collection
6
Vaccines, Synthetic
5
Specimen Handling
5
Early Intervention, Educational
5
Vaginal Smears
4
Methods
4
Engerix-B
4
fludarabine
3
epigallocatechin gallate
3
artesunic acid
3
artemisinin
3
Watchful Waiting
3
Surveys and Questionnaires
3
Patient Navigation
3
Paclitaxel
3
Imiquimod
3
Hepatitis A Vaccines
3
Cyclophosphamide
3
halofantrine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Papillomavirus Infections
×
Cantharidin
×
Clear all
NCT03981822
2024-11-27
CARE-1
Verrica Pharmaceuticals Inc.
Phase 2
Completed
105 enrolled
24 charts